Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8478640 | 0.83 | MAPT (0.62) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL21647153 | 0.82 | LMNA (0.44) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL8477934 | 0.79 | MAPT (0.57) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL7285309 | 0.78 | MAPT (0.50) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL8477456 | 0.77 | MAPT (0.54) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL9007487 | 0.77 | MAPT (0.80) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL27686594 | 0.76 | MAPT (0.49) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL19612191 | 0.75 | MAPT (1.00) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL4469014 | 0.75 | MAPT (0.65) | MAPTTDP1L3MBTL1MAPK1CYP2C19 | |
| SCHEMBL5674481 | 0.75 | MAPT (0.76) | MAPTTDP1L3MBTL1MAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1829709-A | Bicyclic imidazol derivatives against flaviviridae | GENELABS TECH INC (US) | 2006-09-06 | — | — | CN | claimed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | claimed |
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| CN-1829709-A | Bicyclic imidazol derivatives against flaviviridae | GENELABS TECH INC (US) | 2006-09-06 | — | — | CN | disclosed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | HAVCR2, MAVS, ZC3HAV1 | MAPT 2748/4885TDP1 2768/4885L3MBTL1 1221/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | MAPT 2748/4885TDP1 2768/4885L3MBTL1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.